Phim Sex Filme Porno PORNO GRÁTIS Filme Porno Phim Sex Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe | Pharmacy News EU

Article written

  • on 30.12.2013
  • at 12:00 AM
  • by admin

Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn’s disease (see also Biogen Idec).
Under the agreement, Biogen Idec will be responsible for commercialization of these product candidates across Europe, where there already exists a strong market for biosimilars and a defined regulatory pathway. The agreement with Samsung Bioepis aligns with Biogen Idec’s broader corporate objectives of remaining focused on its core business, while leveraging its expertise in manufacturing and specialty markets to meet the need for biosimilar therapies.
“This is a unique opportunity for us to leverage our experience in developing and manufacturing high-quality biologics in therapeutic areas where we are deeply focused, and provide medicines to patients where there is a significant societal need,” said Tony Kingsley, executive vice president of global commercial operations for Biogen Idec. “As a company that aims to make a difference in the lives of patients with serious diseases, we are excited by the potential to offer additional highly effective therapies in critical areas where there is growing demand.”
Keywords for this news article include: Biogen Idec, Marketing and Licensing Agreements.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
(c) 2013 Pharma Business Week via NewsRx.com

subscribe to comments RSS

Comments are closed